The marketer of the first naloxone nasal spray available OTC in the US is extending the shelf-life of its 4mg emergency treatment for opioid overdose from three years to four years while the second spray available OTC is being distributed for the first time.
The Food and Drug Administration on 17 January announced that Emergent BioSolutions Inc. is extending the shelf-life of newly manufactured...







